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Abstract
Author Manuscript

Research during the last decade has significantly advanced our understanding of the molecular
mechanisms at the interface between the nervous system and the immune system. Insight into
bidirectional neuroimmune communication has characterized the nervous system as an important
partner of the immune system in the regulation of inflammation. Neuronal pathways, including the
vagus nerve-based inflammatory reflex are physiological regulators of immune function and
inflammation. In parallel, neuronal function is altered in conditions characterized by immune
dysregulation and inflammation. Here, we review these regulatory mechanisms and describe the
neural circuitry modulating immunity. Understanding these mechanisms reveals possibilities to
use targeted neuromodulation as a therapeutic approach for inflammatory and autoimmune
disorders. These findings and current clinical exploration of neuromodulation in the treatment of
inflammatory diseases defines the emerging field of Bioelectronic Medicine.
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1. Introduction
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The more we know about the molecular mechanisms of disease, the better therapeutic
approaches we can design to treat and potentially cure it. This is one of the main principles
of clinically oriented research, which has led to successful treatments of many disorders.
Still, there are numerous diseases with no adequate treatments despite serious research
efforts, employing state of the art technology, to identify new molecular therapeutic targets.
There are several reasons for this failure to successfully translate research discoveries into
the clinic, including the complexity of mechanisms regulating these targets within the scope
of major biological events and the alteration and dysfunction of these regulatory
mechanisms in disease settings. While this may sound trivial to many and the need for new
multidisciplinary approaches seems obvious, the path forward is not always clear.
Here we outline important aspects of research performed on crossroads between
neuroscience and immunology, which holds a great promise to significantly advance the
treatment of a broad spectrum of diseases characterized by immune dysfunction. This work
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has provided important insight into the role of neurons as partners of immune cells in the
regulation of inflammation, which has significant implications in disease pathogenesis. It
has now become clear that neurons sense inflammatory products and that neuronal activity is
modulated in inflammatory conditions. Moreover, neurons can detect molecules associated
with pathogen invasion simultaneously, or even before immune cells [1]. The nervous
system is positioned to mount fast and directed responses to inflammatory stimuli through
reflex-like mechanisms and to regulate immune function and inflammation [2–4]. These
neuron-immune cell interactions can be exploited therapeutically in inflammatory and
autoimmune conditions, obesity-driven disorders and other diseases characterized by
aberrant inflammation [5,6]. A growing body of mechanistic insight into the pathways and
mechanisms at the interface of the nervous system and the immune system has also led to a
major conceptual switch in designing therapeutic approaches. These new concepts within
the scope of the emerging field of Bioelectronic Medicine explore selective
neuromodulation directed to specific molecular targets in disease treatment. Although this
field is in its infancy, device-generated modulation of vagus nerve activity has already
started yielding successful translational applications in human disease [7].

2. Nervous system and immune system features favoring interaction and
loci of neuroimmune communication

Author Manuscript

The nervous and the immune systems evolved to respond to external and internal stimuli.
The nervous system integrates physiological processes and controls homeostasis through
neuronal networks. The immune system provides defense responses against infection and
injury through immunity. A long history of mutual disregard between Neuroscience and
Immunology has been followed by research bridging the two disciplines and demonstrating
a variety of neuro-immune interactions.
2.1. The nervous system flexible authority

Author Manuscript

The nervous system regulates a broad spectrum of physiological processes. Constant
communication between physiological systems operating in peripheral (abdominal and
thoracic) organs and the brain mediates this regulation. A significant part of this
communication is based on neural reflex mechanisms such as the neural regulation of blood
pressure and gastrointestinal function and takes place through the neurons of the autonomic
nervous system. The vagus nerve is a major constituent of the parasympathetic division of
the autonomic nervous system. This nerve contains afferent (or sensory) fibers that are
specialized in transmitting signals from peripheral organs to the brainstem, and efferent (or
motor) fibers that originate in the brainstem medulla oblongata, innervate major peripheral
organs, and control heart rate, gastrointestinal motility and other vital physiological
functions [6]. Neural networks involving higher, forebrain re[8]gions also participate in the
coordinated neural regulation of physiological functions. Vagus and brain neuronal activity
is constantly modulated in response to peripheral physiological alterations and their
deviations in disease settings. These peripheral alterations also trigger brain-derived
responses to maintain homeostasis.
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2.2. The immune complex defense
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The immune system detects pathogen invasion, tissue injury or self danger signals, mounts
responses to contain, neutralize and eliminate these potentially damaging stimuli and forms
an immunological memory that facilitates this defense strategy upon encountering similar
challenges in the future. These complex regulatory processes represent immunity.
Leukocyte/neutrophil and monocyte migration to the site of injury or infection is an early
and important event in the immune defense repertoire [9]. Pathogen fragments and
molecules associated with tissue injury interact with molecular sensors, including toll-like
receptors (TLRs), NOD-like receptors (NLRs) and other pattern recognition receptors on the
cell surface or in the cytoplasm of macrophages and other innate immune cells. These
interactions trigger immune cell activation through intracellular cascade mechanisms,
resulting in activation of NF-κB and other transcription factors with the release of cytokines
including TNF, IL-1β, IL-6, and HMGB1. In addition to cytokines, the release of other
inflammatory molecules such as prostaglandins and leukotrienes mediates inflammation,
which is aimed at neutralizing the invading pathogen and tissue repair. Macrophages and
dendritic cells also are antigen-presenting cells, linking innate immune factors with adaptive
immunity, characterized by T and B cell responses, which also contribute to containing the
inciting stimulus and forming an immunological memory. The release of cytokines is
essential in inflammation, which normally is localized and timely resolved. The resolution
of inflammation is an active process guided by molecular mediators collectively termed
resolvins and protectins, and aimed at restraining leukocyte infiltration and activation
phagocytosis of pathogen fragments by macrophages [9–11]. However, due to
circumstances that are not yet well understood, inflammation resolution might be
compromised and the inflammatory response might become systemic and chronic with
deleterious consequences. There are various pathophysiological scenarios in which
excessive release of TNF and other pro-inflammatory cytokines in the circulation mediates
secondary tissue damage that can be debilitating or lethal. Persistent, non-resolving chronic
inflammatory responses are implicated in the pathology of several disorders, including
sepsis, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disease, the
metabolic syndrome and diabetes.
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In the brain, inflammation is predominantly mediated by two types of cells with immune
function - microglia and astrocytes [12,13]. At physiological conditions these cells are
important modulators of neuronal structure and function; they play a role in neurogenesis,
synaptic formation, plasticity and remodeling through the release neurotrophins and
complement neurotransmission through the release of gliotransmitters [12–15]. Astrocytes
also are important constituents of the blood brain barrier [13]. Microglia provide immune
surveillance in the CNS/brain [12,13]. Immune activation in the CNS and the brain in
particular occurs through mechanisms similar to peripheral innate immune activation [14].
Brain infection, brain injury, and neurodegenerative processes trigger microglia activation
through TLRs and other pattern recognition receptor-mediated signaling with the release of
TNF, IL-1β, IL-6, reactive oxygen species and other pro-inflammatory molecules, which
mediate neuroinflammation [14,16,17]. Astrocyte activation with the release of
inflammatory mediators also contributes to inflammation in the brain [13]. These brain
immune responses and inflammation are directed towards repair and restoration of neuronal
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integrity and function. However, chronic neuroinflammation exacerbates neuronal damage,
associated with further neuronal dysfunction [12,17].
2.3. The neuroimmune common ground
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Neurons and immune cells interact with each other. Cooperation between neurons and innate
immune defense mechanisms is in play even in invertebrates where the immune system and
the nervous system have their phylogenetic origins. The simple nervous system of
Caenorhabditis elegans, with 302 neurons – contains neurons specialized in controlling a
noncanonical unfolded protein response pathway required for innate immunity in this soil
nematode [18]. Specific aspects of neuron-immune cell interactions in the periphery and in
the CNS have been actively studied. In the periphery these interactions have been
highlighted in neurogenic inflammation [19]. In this scenario somatosensory neurons
(neuroceptors) detect cytokines and other inflammatory products from activated immune
cells in response to bacterial invasion and mediate inflammatory pain. In addition, these
neurons - in an antidromic fashion- release substance P and other mediators, which cause
vasodilation by acting on endothelial and smooth muscle cells, and serve as immune cell
attractants and activators of immune cells, including dendritic cells, mast cells and T
lymphocytes [19]. These neuro-immune interactions mediate integrated protective
mechanisms. However, constant amplification of neurogenic inflammation may have
implications in the pathogenesis of autoimmune diseases and allergic conditions [19].
Important insight into the role of neurons in sensing pathogen-associated molecules was
provided by Clifford Woolf and colleagues. They have recently found that the presence of
bacterial (S. aureus) infection activates neuroceptors without triggering innate and adaptive
immune activation as a mediating event, because it does not involve neutrophils, monocytes,
T cells, B cells and signaling through TLR2 and MyD88 [1]. Instead, S. aureus activates
these sensory neurons though induction of calcium flux and action potentials in a direct
manner through the release of N-formyl peptides and the pore-forming toxin alphahemolysin. In addition, these sensory neurons release neuropeptides that inhibit innate
immune activation within an axon-reflex mechanism [1]. Specific nociceptor ablation
abrogates pain sensation, which is also associated with increased local inflammation and
lymphadenopathy, indicating a tonic anti-inflammatory role of these reflex mechanisms [1].
In the CNS/brain, microglial activation and astrogliosis mediate neuroinflammation.
Persistent brain inflammatory responses have been associated with promoting
neurodegeneration and contributing to neuronal dysfunction in the context of Alzheimer’s
disease, multiple sclerosis, Parkinson’s disease, and the sequelae of traumatic brain injury
and stroke [20].

Author Manuscript

3. Bidirectional immune-brain communication and the emergence of the
reflex concept
A neuro-immune dialog bridging the brain and the immune system also takes place.
Peripheral immune cell activation with the release of cytokines and other immune molecules
is communicated to the brain through neural and humoral mechanisms and triggers brainderived immunoregulatory output through neural and neurohormonal pathways [2,6,21–25].
Infiltration of immune cells, including monocytes, T cells, and neutrophils in the brain has
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also been described [25]. Linda Watkins and colleagues have demonstrated an important
role of afferent vagus neurons in immune-to-brain communication [26]. Cytokines and other
inflammatory molecules interact with afferent vagus neurons transmitting the signals to the
nucleus tractus solitarius (NTS) in the brainstem, where these signals are integrated with
efferent vagus nerve signaling through neurons residing in the dorsal motor nucleus of the
vagus (DMN) [8] (Fig. 1). Efferent vagus nerve cholinergic signaling provides a conduit of
brain-to-immune communication for inhibition of excessive release of TNF and other proinflammatory cytokines [27]. This neuronal circuit is termed “the cholinergic antiinflammatory pathway” [27] (Fig. 1). This discovery has been shortly followed by the
identification of a specific receptor on macrophages and other immune cells - the alpha7
nicotinic acetylcholine receptor (α7nAChR), as a mediator of anti-inflammatory cholinergic
output [28]. Together these findings defined a new physiological immunoregulatory
mechanism - the inflammatory reflex. [2] (Fig. 1). Afferent and efferent vagus nerve fibers
within the inflammatory reflex provide a physiological interface between the immune
system and the brain, for communication and control of excessive pro-inflammatory
signaling. Recent developments in our understanding of the inflammatory reflex have
highlighted that the efferent vagus nerve communicates with the splenic nerve to suppress
excessive pro-inflammatory cytokine responses and inflammation [29–31] (Fig. 1).
Although splenic nerve fibers are catecholaminergic, vagus nerve stimulation results in
increased levels of acetylcholine in spleen, and vagotomy or splenic nerve transection
decreases it [32]. Insight into this interesting phenomenon has revealed that a subset of
splenic T cells, which contain functional choline acetyltransferase, is a source of
acetylcholine in spleen with a mediating role in the inflammatory reflex [31]. This
acetylcholine, released under vagus nerve control, mediated through splenic nerve
catecholaminergic output, interacts with α7nAChR on macrophages and other immune cells.
This interaction causes suppression of macrophage activation and results in lower TNF and
other pro-inflammatory cytokine release via intracellular mechanisms, involving suppression
of NF-κB nuclear translocation. The vagus nerve-based inflammatory reflex is a
prototypical mechanism of neuroimmunomodulation in the context of physiological reflex
regulation. Ongoing work has identified other neurons and circuits that regulate immune
function. For instance, a neural mechanism controlling autoreactive T cell access to the CNS
of mice with autoimmune encephalomyelitis has been recently demonstrated [33]. In this
animal model of multiple sclerosis, dorsal vessels of the L5 spinal cord have been identified
as an entry point for pathogenic CD4+ T cells to enter the CNS [33]. A complex interaction
among sensory neurons innervating the soleus muscles and catecholaminergic (sympathetic)
output activates an IL-6-mediated inflammatory amplification in endothelial cells with
increased generation of chemokines, which facilitates T cell entry into the CNS [33,34].
Another study has demonstrated the critical importance of neural mechanisms in
immunosuppression after stroke and the specific role of catecholaminergic modulation of
hepatic invariant NKT cells as a central event in this context, and has suggested implications
of neural circuitry in pneumonia development and mortality after stroke [35].
Catecholaminergic signaling was also recently implicated in a neural circuit controlling
lymphocyte trafficking [36]. Neuronal catecholaminergic output, mediated through
lymphocyte β2 receptor signaling, which is associated with chemokine receptors suppresses
lymphocyte egress from lymph nodes. The physiological importance of this neural
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mechanism, which reduces lymphocyte recruitment into peripheral tissues is related to
suppression of T cell mediated tissue damage [37,38]. These reports highlighted the broader
scope of neural circuitry that is organized in a reflex manner in controlling immunity by
regulating a variety of immune responses at different anatomical locations [4,5].

4. A close look at the efferent vagus nerve immunoregulatory circuitry
Research during the last 10–15 years utilizing vagus nerve stimulation, surgical transection
of the vagus nerve (vagotomy) and state-of-the-art genetic, pharmacological and
immunological methodology generated abundant mechanistic insight into vagus nerve
neurocircuitry implicated in immune regulation and the neurophysiology of the
inflammatory reflex.
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4.1. Vagus nerve stimulation
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Electrical cervical vagus nerve stimulation (VNS) has been instrumental for demonstrating
the efficacy of efferent vagus nerve signaling in suppressing serum and hepatic TNF and
other pro-inflammatory cytokine levels and attenuating systemic endotoxemic shock [27].
Acetylcholine, an important mediator of efferent vagus nerve signaling has been found to
suppress endotoxin-stimulated macrophage release of TNF, IL-1β, IL-6 and IL-18 [27].
These discoveries have led to numerous subsequent studies that have elucidated
immunoregulatory vagus nerve signaling in various conditions. In rats with acute
hypovolemic hemorrhagic shock and systemic inflammation, VNS suppresses serum TNF,
hepatic TNF gene expression and hepatic NF-κB activation by blocking IκB degradation;
these effects parallel alleviated hypotension and an increased survival time [39]. In murine
postoperative ileus, VNS suppresses intestinal muscle layer resident macrophage activation
and alleviates the condition [40]. Activation of the signal transducer and activator of
transcription (STAT) in intestinal macrophages was shown to play a role in mediating VNS
effects in this context [40]. VNS suppresses leukocyte trafficking to a subcutaneous site of
inflammation, a finding implicating vagus nerve circuitry in the regulation of leukocyte
migration across the endothelium during local inflammation [41]. A very recent study
reported that single pulse low frequency VNS stimulation is sufficient to suppress TNF
release in endotoxemia [42]. This finding is important because it suggests further
exploration of a very short duration of VNS in a broader scope of inflammatory conditions,
including asthma, where continuous VNS should be avoided because of potential
bronchoconstriction effects. In addition to efferent signals, the activation of afferent vagus
nerve signaling contributes to anti-inflammatory effects, an observation suggesting that VNS
may trigger brain-derived immunoregulatory output [42]. VNS also suppresses peripheral
hemorrhage, which suggests important therapeutic implications of VNS in preventing
uncontrolled bleeding [43]. In addition to electrical VNS, transcutaneous vagus nerve
stimulation suppresses serum TNF levels in murine endotoxemia [44]. The efficacy of this
approach of VNS has been shown in preclinical settings of sepsis, a notorious clinical
syndrome that is characterized by dysregulation of immune and other physiological
responses and which is the number one killer in the ICUs. VNS initiated in a clinicallyrelevant time frame – 24 hours after the onset of cecal ligation and puncture-induced murine
sepsis significantly suppresses serum levels of HMGB1 - a pro-inflammatory molecule and
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a pivotal cytokine mediator of sepsis lethality and improves survival [44]. VNS by
implanted device-generated electrical stimulation at relatively high frequency is clinically
approved for the treatment of epilepsy and pharmacoresistant depression [45]. In addition to
acute settings, recent studies have evaluated the efficacy of VNS generated by implanted
devices in murine models of chronic inflammatory disease. Low frequency VNS through
implanted cuff electrode (once daily for 7 days) significantly alleviates the disease score,
inflammation and other underlying pathology in rats with collagen-induced arthritis [46].
Implanted VNS (3 hours of stimulation per day for 5 days) in freely moving rats
significantly alleviates colonic inflammation and severity of colitis [47]. These studies with
implanted VNS in animals with chronic inflammatory conditions have paved the path to
ongoing clinical trials in patients with rheumatoid arthritis and inflammatory bowel disease.
4.2. Vagotomy
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In contrast to VNS, interruption of vagus nerve signaling through vagotomy results in higher
pro-inflammatory cytokine levels in endotoxemic animals, pointing to a tonic antiinflammatory role of the vagus nerve [27]. Cervical bilateral vagotomy provides an
approach for a total interruption of vagus nerve signaling. However, it is associated with
high lethality, which limits the use of this approach to acute experiments with anesthetized
animals. Therefore, bilateral subdiaphragmatic vagotomy and unilateral cervical vagotomy
have also been explored in inflammatory settings. For instance, bilateral subdiaphragmatic
vagotomy prior to dextran sodium sulfate (DSS)-induced murine colitis results in higher
colonic levels of TNF and other pro-inflammatory cytokines, increased disease activity
indices and elevated macroscopic and histological scores as compared to sham-operated
mice [48]. Vagotomy does not alter disease severity in M-CSF-deficient mice, which
indicates a role for macrophages in mediating these vagus nerve effects [48]. The diseaseexacerbating effect of subdiaphragmatic vagotomy in a DSS-induced model of colitis has
been recently confirmed and associated with decreased acetylcholine levels in spleen in
vagotomized animals [32]. Subdiaphragmatic vagotomy also increases serum proinflammatory cytokine levels and worsens the disease severity in a dog model of acute
necrotizing pancreatitis, thus indicating a tonic suppressive role of the vagus nerve in the
regulation of pancreatitis inflammation and severity [49]. Moreover, unilateral cervical
vagotomy results in exacerbated pancreatic damage and increased systemic IL-6 levels in a
mouse model of cerulean-induced pancreatitis [50]. Unilateral cervical vagotomy
exacerbates the inflammatory response manifested by increased plasma and cardiac TNF
and IL-1β levels in endotoxemic rats [51]. This approach results in a decreased survival rate
in mice with E. coli pneumonia [52]. Unilateral cervical vagotomy has been instrumental in
making the discovery by Charles Serhan and colleagues that the vagus nerve controls the
resolution of inflammation [11]. Vagotomy results in lower lung and peritoneum gene and
protein expression of the axon guidance molecule netrin-1, which is an important
endogenous pro-resolution molecule in zymosan-induced peritonitis [11]. In addition to
decreased neutrin-1 levels, vagotomy is associated with lower acetylcholine levels, higher
TNF, IL-1β, IL-6, HMGB1, MIP-1α, and KC, and higher leukocyte numbers in
inflammatory exudates. These and additional observations indicate that vagus nerve
signaling regulates a bidirectional synergistic interaction between netrin-1 and other
resolvins, including resolvin D1 to decrease leukocyte migration and stimulate macrophage
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phagocytosis in facilitating inflammation resolution. These findings importantly broaden the
scope of implications of vagus nerve signaling in the regulation of inflammation.
4.3. The vagus nerve - splenic nerve partnership in the inflammatory reflex
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The anti-inflammatory effects of VNS are linked to suppression of TNF in the spleen, the
organ with a major contribution to systemic TNF during endotoxemia [29,30]. These effects
require an interaction between the vagus nerve and the splenic nerve in the efferent arm of
the inflammatory reflex (Fig. 1). Neuroanatomical findings have pointed to the celiac plexus
as an important site of vagus nerve–splenic nerve communication. Efferent vagus nerve
fibers through abdominal subdiaphragmatic anterior and posterior branches innervate the
celiac ganglia and the superior mesenteric ganglion in the celiac plexus [53,54]. Recently,
by utilizing double-labeling for tyrosine hydroxylase and vesicular acetylcholine transporter
(VACh), Hoover and colleagues have demonstrated that cholinergic VAChT-positive nerve
fibers surround abundant neuronal populations with catecholaminergic phenotype in the
celiac ganglia and the superior mesenteric ganglion of mice [55]. These ganglia are a major
source of spleen-projecting catecholaminergic fibers [56–58]. Accordingly, carefully
performed transection of the multiple nerve fibers within the splenic nerve (splenic
neurectomy) abolishes the anti-inflammatory effect of VNS [30]. Catecholaminergic nerve
endings in spleen are in proximity of splenic lymphocytes, including T cells, which contain
choline acetyltransferase (ChAT), the acetylcholine biosynthesizing enzyme [31]. VNS
results in increased acetylcholine release in spleen and this effect is mediated through
splenic nerve catecholaminergic signaling acting on lymphocytes. VNS does not suppress
TNF levels in nude mice, indicating that lymphocytes are required [31]. Passive adoptive
transfer of ChAT-T lymphocytes into nude mice restores the anti-inflammatory efficacy of
VNS, which demonstrates that these acetylcholine-producing cells are necessary [31].
Consequently, acetylcholine acts on the α7 nAChRs on macrophages in the spleen and
suppresses TNF production. Vagus nerve–splenic nerve signaling is implicated in the
regulation of adaptive immune responses [59]. VNS in Streptococcus pneumonia suppresses
the normal migration of B cells to the splenic red pulp, where they become antibodysecreting cells, by retaining the cells in the marginal zone, and decreases B cell antibody
production. Splenic nerve transection significantly abolishes the migration arrest and results
in reorganization of lymphoid architecture [59]. These and other studies in the context of
endotoxemia, sepsis, inflammatory bowel disease [29,30,32] and other inflammatory
conditions have triggered a great deal of interest in the vagus nerve-splenic nerve signaling
in immune regulation. Of note, a study has questioned the vagus nerve-splenic nerve
interaction [60]. Based on a single approach – injection of a retrograde tracer, the suprarenal
ganglia were indicated as the main source of spleen-projecting neurons [60]. In addition, no
labeled neurons in the right celiac ganglion and only a small percentage of these neurons in
the left celiac ganglion were found [60]. No labeled neurons were reported in “superior
mesenteric ganglia of either side” [60], a puzzling anatomical designation, considering the
fact that the superior mesenteric ganglion is a single formation in a very close proximity to
the left celiac ganglion and a part of the celiac-mesenteric ganglionic complex [53–55].
These observations are in clear contrast with other previous studies, utilizing a variety of
approaches to identify the celiac ganglia and the superior mesenteric ganglion as the source
of spleen-projecting catecholaminergic fibers [56–58]. The superior mesenteric-celiac
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ganglia have been demonstrated as the site of origin of catecholaminergic/noradrenergic
innervations of the rat spleen by using selective ganglionectomy and retrograde tracing
combined with immunocytochemical localization of tyrosine hydroxylase [57].
Simultaneously, the celiac-mesenteric gangla have been characterized as a major source of
efferent innervations to the spleen in rats by using retrograde tracing, splenic nerve
transection and catecholamine histofluorescence in the spleen [56]. The celiac ganglia as a
supplier of splenic catecholaminergic innervations has been further demonstrated by using
selective celiac ganglionectomy, tyrosine hydroxylase immunohystochemistry and
norepinephrine determination [58]. Surprisingly, the authors of this study [60] do not
comment on the apparent discrepancy between their observations and these previously
published findings [56–58]. Instead, they focus on determining the effect of VNS on the
electrical activity of suprarenal ganglia neurons to conclude that there is no effect. They also
record whole splenic nerve activity and examine the effect of VNS on it and propose that
activation of efferent vagus nerve signaling does not alter splenic nerve activity [60]. As
previously demonstrated, splenic nerve catecholaminergic fibers innervate splenic capsule,
trabeculae, vasculature, and parenchyma [57]. In addition to vasomotor fibers, whose
activity is usually recorded there are other catecholaminergic fibers branching in the
parenchyma and associated with T cell and other immune cell interactions [31,61–63]. The
lack of adequate methodological description of splenic nerve isolation and recording in this
study [60] makes it virtually impossible to assess what splenic neuron activity was recorded.
A preponderance of data indicates the importance of efferent vagus nerve-splenic nerve
functional integrity in controling spleen pro-inflammatory cytokine production [29–32].
4.4. The interface with, and within the immune component
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α7nAChR is an important receptor mediator in the neural vagus nerve control of immune
function. This role of the α7nAChR was initially indicated by the observation that in
contrast to its suppressive effect in wild type (WT) mice, VNS does not significantly alter
TNF levels in α7nAChR KO mice during endotoxemia [28]. In addition, treatment with the
centrally-acting acetylcholinesterase inhibitor galantamine, whose brain-mediated mode of
anti-inflammatory activity requires an intact vagus nerve as a brain-to periphery conduit,
also fails to inhibit systemic TNF levels in endotoxemic α7nAChR KO mice [64]. The
classical neuronal homeopentameric α7nAChR is expressed in the brain and the presence of
α7 subunit containing forms of the receptor has been reported in peripheral autonomic
ganglia and immune cells. Experimental evidence has attributed the cellular origin of the
α7nAChR with a role in mediating cholinergic anti-inflammatory output to immune cells.
For instance, the release of pro-inflammatory cytokines by macrophages from α7nAChR
KO mice or macrophages with α7nAChR anti-sense downregulation is not affected by
cholinergic stimulation [28]. Furthermore, α7nAChR deficiency in the immune system
generated by adoptive transfer of α7nAChR KO bone marrow cells to irradiated WT mice,
abolishes VNS inhibition of serum TNF levels during endotoxemia while α7nAChR
neuronal deficiency by transferring WT bone marrow cells to irradiated alpha7 KO mice
does not alter this VNS anti-inflammatory effect [65]. This mechanistic insight has allowed
studying the anti-inflammatory efficacy of small molecule α7nAChR agonists at various
inflammatory conditions. GTS-21 was the first selective α7nAChR agonist whose antiinflammatory properties were demonstrated in murine models of pancreatitis [50],
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endotoxemia and severe sepsis [66]. Importantly, treatment with GTS-21 initiated within a
clinically relevant time frame (24 hours after the onset of severe sepsis), significantly
improves survival and lowers serum levels of HMGB1, a late mediator of the disease [66].
Another selective endogenous α7nAChR agonist is choline, a byproduct of acetylcholine
degradation. Choline suppresses serum TNF and HMGB1, and improves survival in
endotoxemia and experimental sepsis in a clinically-relevant time frame [67]. The antiinflammatory effects of choline are mediated through α7nAChR-signaling, as demonstrated
by using α7nAChR KO mice [67]. Several other studies have evaluated anti-inflammatory
efficacy of α7nAChR agonists in endotoxemia, sepsis, rheumatoid arthritis, mechanical
ventilation-induced lung injury, postoperative neuroinflammation, ischemia-reperfusion
injury and other inflammatory conditions [68–71]. These studies have also contributed to
delineating intracellular mechanisms downstream of the α7nAChR with a role in inhibiting
TNF and other pro-inflammatory cytokine production. These mechanisms involve inhibition
of the nuclear translocation of the transcription factor NF-κB [21,66,67,72] and activation of
the JAK2-STAT-3 pathway [40]. In addition to triggering anti-inflammatory signal
transduction through activation of the α7nAChR on the immune cell surface, a very recent
report has revealed a role for cholinergic activation of the α7nAChR expressed on the
mitochondrial membrane in immune regulation through inhibition of the inflammasome
[73]. Immune cell activation is accompanied by intracellular accumulation of acetylcholine,
which interacts with the mitochondrial α7nAChR resulting in stabilization of mitochondrial
membrane permeability, preventing mitochondrial DNA release and consequently,
inhibition of the NLRP3 inflammasome activation [73].

5. The remote immunomodulatory switches in the brain
Author Manuscript

The brain is an active participant in the regulation of immunity; it receives and integrates
signals for altered immune homeostasis and mounts responses to control peripheral immune
function through the inflammatory reflex and other pathways. We have begun to reveal the
neuromodulatory and neuroreceptor mechanisms with a role in this regulation and evaluate
therapeutic anti-inflammatory approaches based on brain cholinergic activation.
5.1. Relevant brain neuroanatomical organization
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Neuronal interactions between the NTS, DMN and area postrema within the dorsal vagal
complex integrate the vagus nerve-based inflammatory reflex at the level of the brainstem
(Fig. 1). The dorsal vagal complex is interconnected with the hypothalamus, thalamus,
hippocampus, amygdala, medial prefrontal and other cortex regions. These reciprocal
circuits provide neuroanatomical and functional substrates for modulation of vagus nerve
activity and the inflammatory reflex, and intersection with brain networks associated with
behavioral, endocrine and metabolic regulation [6,74]. Experimental evidence indicates a
role for cholinergic signaling in the brain modulation of the inflammatory reflex. The brain
cholinergic system is a major neuromodulatory system with widespread innervations,
originating from two major locations, the basal forebrain and the mesopontine tegmentum
[75,76]. Basal forebrain cholinergic pathways predominantly innervate the cortex
(neocortex), hippocampus, olfactory bulb and amygdale [75,76]. Cholinergic innervations
from the mesopontine pedunculopontine tegmental and laterodorsal tegmental nuclei
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innervate, among other brain regions, the thalamus, hypothalamus and cerebellum [75,76].
Acetylcholine, released from cholinergic axons interacts with two types of receptors on
cholinoceptive neurons; muscarinic M1 through M5 subtypes of metabotropic, G proteincoupled receptors and nicotinic ionotropic receptors. Muscarinic acetylcholine receptors
(mAChRs) and specifically the M1 subtype play a major role in processing cholinergic
transmission in the brain [77]. The cortex, hippocampus, hypothalamus and other brain areas
innervated by cholinergic pathways interact directly or through multisynaptic pathways with
the dorsal motor complex, the brainstem integrative center of the inflammatory reflex
[6,74,78–80].
5.2. Brain muscarinic receptor–mediated networks regulate peripheral inflammatory
responses
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Brain mAChR subtypes have different synaptic locations and function in cholinergic
transmission. The M1 mAChR is predominantly postsynaptic on cholinoceptive neurons in
the cortex, hippocampus and other brain areas. The M2 mAChR is mostly presynaptic and
its role in the cholinergic synapse is inhibition (autoinhibition) of acetylcholine release.
Central, intracerebroventricular administration of an M1 mAChR agonist or a M2 mAChR
antagonist significantly suppresses serum TNF levels in endotoxemic animals [81]. Central
mAChR ligand administration also significantly increases efferent vagus nerve activity
indicated by activation of the high frequency component of heart rate variability based on
ECG analysis [81]. These observations have provided experimental evidence for a role of
brain mAChR- mediated cholinergic signaling in the regulation of peripheral inflammation
through functional integration with efferent vagus nerve activity (Fig. 1). They also suggest
that brain mAChR signaling may mediate the previously demonstrated central activation of
the cholinergic anti-inflammatory pathway by the anti-inflammatory compound CNI-1493
[82], identified as a mAChR ligand. Central administration of the M1 mAChR McN-A-343
and the M2 mAChR antagonist methoctramine have recently been shown to inhibit colonic
TNF, IL-6 and other pro-inflammatory cytokines and alleviate disease severity in two
models of colitis [32,83]. Increased acetylcholine levels in spleen of mice treated with McNA-343 mediate anti-inflammatory drug efficacy in colitis and these effects require signaling
along the vagus nerve and splenic nerve, because they are abolished in mice with vagotomy
and splenic nerve transection [32]. An anti-inflammatory role of brain mAChRs has been
demonstrated in experimental models of hemorrhagic shock [84,85] and in mediating the
anti-inflammatory efficacy of acupuncture [86]. In addition, peripheral administration of the
centrally-acting M1 mAChR agonist xanomeline significantly suppresses serum TNF and
improves survival in murine endotoxemia [87]. Anti-inflammatory effects of xanomeline are
mediated through brain mAChRs and require an intact vagus nerve-splenic nerve axis [87].
Interestingly, xanomeline provides a long-lasting anti-inflammatory protection, indicated by
the observation that drug administration as early as 20 hours prior to LPS is efficient in
suppressing serum TNF levels and improving survival in endotoxemic mice [87]. This longlasting drug efficacy is associated with alterations in splenic leukocyte subpopulations
including a proportional increase in T cell numbers in parallel with reduced splenocyte
responsiveness to inflammatory stimulation. In addition, current studies indicate that
peripheral administration of a centrally-acting compound, which belongs to the latest
generation of positive allosteric modulators of the M1 mAChRs suppresses pro-

Immunol Res. Author manuscript; available in PMC 2016 December 01.

Pavlov and Tracey

Page 12

Author Manuscript
Author Manuscript

inflammatory cytokine levels in endotoxemia and improves survival in endotoxemia and
severe sepsis (unpublished data). Preclinical development of xanomeline and this latest
generation of compounds has been mainly driven by the search for mAChR ligands that are
more efficient and devoid of side effects in the context of Alzheimer’s disease and
schizophrenia [88–92]. Xanomeline treatment of patients with schizophrenia significantly
alleviates positive and negative symptoms and cognitive deterioration [90]. Peripheral
inflammation reported in the context of schizophrenia has been proposed to have a causative
role in disease pathology [93,94]. In light of ameliorating peripheral inflammation by
xanomeline [87], one may now ask the intriguing question of whether anti-inflammatory
effects of xanomeline contribute to its efficacy in clinical settings of schizophrenia. In
contrast to centrally-acting cholinergic modalities, anticholinergic drugs, which are
frequently prescribed to elderly have been associated with exacerbated inflammatory
responses to endotoxemia in a neurodegenerative tauopathy murine model [95,96].
Importantly, an increase in IL-1β expression in spleen and brain is significantly more
pronounced in endotoxemic mice pretreated with trihexyphenidyl - a centrally-acting M1
mAChR antagonist as compared with another compound with a weaker CNS activity [95].
These findings suggest that inhibition of brain cholinergic M1 mAChR signaling
exacerbates inflammation. It is interesting and potentially important that while modulation
of brain mAChRs and specifically activation of the M1 subtype have been linked to antiinflammatory effects, cholinergic activation through peripheral mAChR-mediated
mechanisms has been associated with pro-inflammatory effects as demonstrated in patients
with irritable bowel syndrome [97]. In addition, Kawashima and colleagues have shown that
genetic ablation of both M1 and M5 mAChRs results in lower levels of TNF and IL-6
released by splenic mononuclear leucocytes incubated with ovalbumin, suggesting a tonic
pro-inflammatory role of these receptors [98].
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5.3. Borrowing from Alzheimer’s disease drugs to study inflammation:
acetylcholinesterase inhibitors as anti-inflammatory agents
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Diminished acetylcholine release in the brain due to neurodegeneration involving basal
forebrain cholinergic neurons is an important pathophysiological feature in Alzheimer’s
disease. Accordingly, the current treatment of cognitive deterioration associated with
Alzheimer’s disease is largely based on the use of centrally-acting acetylcholinesterase
inhibitors, which inhibit acetylcholine breakdown, thus potentiating brain cholinergic
signaling. These drugs also have powerfull anti-inflammatory properties. Central cholinergic
activation by peripheral administration of the centrally-acting AChE inhibitors galantamine
and huperzine-A results in significant inhibition of serum TNF and improved survival in
endotoxemic mice [64]. The anti-inflammatory effect of galantamine is mediated through
brain mAChRs, depends on the integrity of the vagus nerve and is abolished in α7nAChR
KO mice [64]. These findings and the reported stimulation of efferent vagus nerve activity
by galantamine [99], indicated that CNS mAChR-mediated effects of galantamine are
functionally linked to activation of the vagus nerve-based cholinergic anti-inflammatory
pathway (Fig. 1). Interestingly, single dose galantamine administration provides at least a 20
hours time window of anti-inflammatory protection, in line with a similar long-lasting effect
of the M1 mAChR agonist xanomeline in endotoxemic mice [87]. Galantamine treatment of
mice with colitis significantly alleviates colonic inflammation and disease severity,
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associated with increased acetylcholine release in spleen, interacting with the α7nAChRs on
dendritic cells [32]. Pharmacological blockade of brain mAChR receptors, vagotomy and
splenic neurectomy abolish these effects and the increased release of acetylcholine in spleen.
In addition, vagotomy and splenic neurectomy significantly decreases acetylcholine release
in spleen. Together these findings indicate that vagus nerve - splenic nerve interaction
mediates galantamine effects in inflammatory bowel disease [32] (Fig. 1). In addition to
endotoxemia and inflammatory bowel disease, galantamine exerts anti-inflammatory effects
and alleviates the disease progression in a rat model of adjuvant-induced arthritis [100].
Involvement of brain AChE inhibition and peripheral site AChE inhibition has been
described in lowering intestinal inflammation by rivastigmine, another centrally-acting
AChE inhibitor [101]. Several studies further indicate the primary importance of CNS AChE
inhibition in achieving suppression of inflammation at various inflammatory conditions. For
instance, treatment with the centrally-acting AChE inhibitor physostigmine results in higher
level of suppression of the acute colonic inflammatory response in rats with colitis as
compared to treatment with the peripherally-acting neostigmine [102]. In addition, treatment
with the peripherally-acting AChE inhibitor neostigmine fails to alleviate organ injury in
murine endotoxemia [103] and pro-inflammatory cytokine responses associated with
mechanical ventilation [104]. Very recently, treatment with the centrally-acting AChE
inhibitor donepezil has been shown to increase vagal tone, suppress plasma TNF, IL-6 and
IFN-γ levels, attenuate development of hypertension and prevent cardiac remodeling in
spontaneously hypertensive rats [105]. In contrast, treatment with the peripherally-acting
AChE inhibitor pyridostigmine fails to suppress plasma pro-inflammatory cytokine levels
and reduce high blood pressure [105].

Author Manuscript
Author Manuscript

Interestingly, in addition to neuroinflammation, increased levels of peripheral inflammation
have been reported in patients with Alzheimer’s disease, a neurodegenerative disorder
characteristically affecting basal forebrain cholinergic neurons with a resultant diminished
acetylcholine release. There are also reports that treatments with AChE inhibitors of patients
with Alzheimer’s disease result in suppression of peripheral inflammatory responses. For
instance, treatment of patients with Alzheimer’s disease with the AChE inhibitor donepezil,
as compared to untreated patients and healthy controls results in lower gene expression and
protein levels of IL-1β and higher expression and levels of the anti-inflammatory IL-4 in
both unstimulated and phytohemagglutinin-stimulated peripheral blood mononuclear cells
[106]. Furthermore, peripheral blood mononuclear cells isolated from Alzheimer’s disease
patients release higher levels of IL-1β and IL-6 as compared to healthy controls, and
treatment of these patients with the AChE inhibitor donepezil for one month significantly
decreases these levels as compared to prior to treatment conditions [107]. An inverse
correlation between duration of treatment with galantamine, rivastigmine or donepezil of
patients with Alzheimer’s disease and plasma CRP levels also was reported [108]. These
findings highlight a correlation between brain cholinergic hypofunction and elevated
markers of peripheral inflammatory responses in humans. In addition, they suggest that a
boost in brain cholinergic signaling that compensate for this hypofunction may alleviate
peripheral inflammation.
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5.4. The “suffering” brain and its cholinergic symptoms in inflammatory and autoimmune
conditions
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Immune cell activation and inflammation in response to infection or injury can cause a
spectrum of alterations in brain function known as sickness behavior, which is regarded as
an important adaptive mechanism [23–25] (Fig. 2). These brain alterations occur in parallel
with activation of brain-derived neural immunoregulatory pathways. Peripheral
administration of LPS or live bacteria has been instrumental in demonstrating that peripheral
inflammation causes brain pro-inflammatory signaling [109], which has a mediating role in
sickness behavior [23,25] (Fig. 2). Increased systemic cytokine levels in endotoxemia are
associated with activation in pro-inflammatory IL-1β and IL-6 gene expression and
microglial morphological alterations, indicative for microglia activation as early as 4 hours
following peripheral endotoxin administration [110]. These pro-inflammatory alterations
affect the hippocampus, cortex, hypothalamus and other brain areas in a region-specific
manner with no apparent evidence of neurodegeneration as an underlying event [110].
Excessive and non-resolved forms of peripheral inflammation and maladaptive
transformations of sickness behavior can result in deleterious and life-threatening
neurological complications described in several conditions with inflammatory and
autoimmune etiology, including sepsis, chronic liver disease, inflammatory bowel disease,
rheumatoid arthritis, postoperative conditions and obesity [23,69,111–119] (Fig. 2). Many
patients with these disorders suffer depression; it is documented that depressive conditions
exacerbate pro-inflammatory cytokine levels and inflammation, which can affect brain
neurotransmitter systems and brain function [120]. Studying brain cholinergic signaling in
the context of neurological complications associated with inflammatory disorders is
important for several reasons. Brain cholinergic mAChR–mediated signaling regulate longterm potentiation and neuroplasticity, adult neurogenesis, and cerebral blood flow [76,121].
Brain cholinergic pathways are critically implicated in learning, memory, attention,
conscious awareness, sleep, control of movements and peripheral/visceral function
[76,77,122]. Many of these functions are impaired in inflammatory conditions (Fig. 2).
Brain cholinergic mAChR-mediated signaling also has an important role in the regulation of
peripheral cytokine responses and inflammation [6,32,64]. In addition, experimental
evidence indicates that brain cholinergic signaling regulates local brain inflammatory
responses [123–126] and the brain cholinergic system is affected in peripheral inflammatory
and metabolic conditions [110,127–129]. Sepsis is a lethal disorder with peripheral immune
and metabolic dysregulation and neuropsychiatric manifestations. This clinical syndrome is
the most frequent cause of death in the intensive care units [130]. The spectrum of
pathophysiological brain alterations during sepsis is termed sepsis-associated
encephalopathy (SAE), or septic encephalopathy, which ranges from delirium to coma
[114]. SAE can be defined as brain dysfunction, secondary to infection in the body, and no
CNS infection [114]. Delirium is a neurobehavioral syndrome caused by dysregulation of
neuronal activity secondary to broad spectrum of systemic disturbances, including increased
release of pro-inflammatory cytokines and systemic inflammation [114,127,131]. Important
hallmarks in SAE and delirium are altered neurotransmission and cerebral microcirculation
[114]. There is experimental evidence for a major role of cholinergic hypofunction in
delirium [132]. Considering the importance of brain cholinergic signaling in cerebral blood
flow regulation, attention, memory, sleep and the control of voluntary movements,
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decreased cholinergic tone can have a profound contribution to SAE. This cholinergic
hypofunction occurs in parallel, and is interrelated to alterations in other neurotransmitter
systems, including dopaminergic and catecholaminergic hyperactivity, and fluctuations in
GABA-ergic and glutamatergic systems [132]. SAE is an early event in sepsis, can be
developed in upto 80% of the patients and is an independent predictor of mortality and long
term morbidity. The saga of the patients with sepsis does not end with their discharge from
the hospital. Long-term cognitive impairment, functional disability and increased mortality
have been documented in sepsis survivors. Insight into SAE and its long reaching postsepsis consequences holds promises for an early diagnosis and adequate treatments, which
are urgently needed [114]. The pro-inflammatory cytokine HMGB1 was recently identified
as an important mediator of pathogenesis and cognitive impairment in murine sepsis
survivors and as a potential therapeutic target [133,134]. Another option to be explored in
alleviating septic sequelae is the use of galantamine and other AChE inhibitors. These drugs
are already in clinical use in the treatment of cognitive impairment in patients with
Alzheimer’s disease and myopathies such as myasthenia gravis, and they have powerful
anti-inflammatory properties. Another complex and life-threatening neuropsychiatric
syndrome is hepatic encephalopathy, which occurs in the context of acute and chronic liver
failure in cirrhosis associated with metabolic and immune dysregulation [116,117].
Cognitive impairment, deteriorations in sleep, motor activity and coordination, lethargy,
confusion, and ultimate progression into coma define the spectrum of hepatic
encephalopathy [117]. The pathogenesis of hepatic encephalopathy is not well understood.
Increased ammonia levels are thought to play an important role in astrocyte enlargement and
dysfunction in the brain in parallel with microglia activation, oxidative stress and increased
pro-inflammatory cytokine levels [116,117]. Brain cholinergic impairment has also been
reported in patients with cirrhosis and in models of liver failure [135]. Significant increases
in postmortem cortex AChE activity in patients with hepatic encephalopathy and cirrhotic
rats, and a marked decrease in acetylcholine levels in these animals are found [135]. In
addition, treatment with the centrally-acting AChE inhibitor rivastigmine alleviates memory
deficits in a model of liver failure [135]. As summarized by Inouye and colleagues, brain
cholinergic pathways overlap with locations of brain abnormalities and abnormal perfusion
detected by neuroimaging in patients with hepatic encephalopathy, cardiotomy, and
traumatic brain injury [132]. Intriguingly, brain cholinergic impairment coexists with lower
vagal tone in patients with cirrhosis [136,137] and the decrease in vagus nerve activity in
patients with cirrhosis correlates with the degree of hepatic encephalopathy [137]. These
findings provide a rationale for further studies exploring the relationship between altered
brain cholinergic signaling, decreased vagus nerve activity and increased inflammatory
indices in SAE, hepatic encephalopathy and other inflammatory conditions with a deferent
degree of brain impairment for evaluating therapeutic interventions. Promising results from
a very recent clinical trial with rivastigmine in cirrhotic patients with hepatic
encephalopathy represent one of the first validations of this line of therapeutic explorations
[138]. Brain pro-inflammatory signaling, cognitive impairment and behavioral deficiencies
have been described in obesity and type 2 diabetes, diseases with metabolic and
inflammatory etiology [118,119,139–141] (Fig. 2). An autoimmune disease such as type 1
diabetes is associated with alterations in brain cholinergic signaling and impaired cognitive
functions reported in animal models [142,143] and worsened cognitive domains in patients

Immunol Res. Author manuscript; available in PMC 2016 December 01.

Pavlov and Tracey

Page 16

Author Manuscript

[141]. Another notorious example of an autoimmune disease with characteristic neurological
complications is systemic lupus erythematosus (Fig. 2). Betty Diamond and colleagues have
provided important insight into the neurological complications of this autoimmune condition
pointing to a mediating role of peripheral antibodies targeting the brain glutamatergic
system [144–147]. These findings have provided a rationale for developing new therapeutic
modalities.
5.5. Device-generated modulation of brain neurocircuitry as a future anti-inflammatory
approach
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The brain cholinergic system provides widespread innervations to the cortex, other forebrain
areas, brainstem and cerebellum and controls a variety of brain functions [75,76]. In
addition, brain cholinergic mAChR mediated signaling plays a role in controlling
cardiovascular and gastrointestinal function, pancreatic secretion and other peripheral
physiological processes via vagus nerve mediated mechanisms [85,148–151]. In addition to
pharmacological modalities cholinergic pathways in the brain can be modulated by using
electrical or other forms of device-generated output. Device-generated brain modulation,
including deep brain electrical stimulation, transcranial magnetic stimulation, and
transcranial direct current stimulation has been in clinical or exploratory use for various
neurological conditions [152,153]. There is a growing interest in these approaches judging
by the increasing number of relevant publications as recently summarized [152]. In parallel,
optogenetic modulation has been actively utilized as a highly selective methodology to
provide specific mechanistic insight into the physiological role of brain neuronal circuits.
Electrical and other forms of device-generated output have been currently used in studying
the role of specific cholinergic pathways in the regulation of inflammation. Identifying brain
networks with a role in peripheral neuromodulation may indicate future implications of deep
brain stimulation or other non-invasive approaches in the treatment of inflammatory and
autoimmune conditions.

6. Neurocircuitry and inflammation in obesity and cancer

Author Manuscript

The prevalence of obesity and the associated metabolic syndrome has reached epidemic
proportions. The serious health threat, which obesity and the metabolic syndrome represent,
is associated with the increased risk of developing type 2 diabetes, cardiovascular disease,
cancer and other debilitating and life-threatening disorders [154]. The metabolic
dysregulation in obesity is importantly interrelated with chronic low-grade inflammation as
major underlying events in insulin resistance, fatty liver disease and other obesity-associated
complications [6,155–157]. The expanded abdominal adipose tissue, infiltrated with
macrophages, neutrophils, T cells and other immune cells is considered to be the main
source of inflammation in obesity [155,156]. In addition to immune cells, enlarged
adipocytes, which are typically a fat storage, become active cytokine- and adipokineproducing cells in this microenvironment [156,158]. Dysregulated release of adipokines,
including leptin, resistin, adiponectin, and TNF, IL-1β, IL-6 and other cytokines mediate
obesity-associated inflammation [6,155,156,158]. The vagus nerve within reflex
mechanisms plays an important role in metabolic homeostasis. In addition to mediating
satiety, afferent vagus nerve fibers, through associated mechanoreceptors, chemoreceptors,
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and specific metabolite receptors transmit alterations in peripheral levels of metabolic
molecules, including cholecystokinin, peptide YY, and glucagon-like peptide-1 to the
brainstem NTS and then these signals reach the hypothalamus and other brain areas [6].
Efferent vagus nerve cholinergic output regulates pancreatic insulin and glucagon secretion
and hepatic gluconeogenesis, the main determinant of fasting blood glucose levels [6]. There
is also experimental evidence for compromised vagus nerve regulatory function in obesity
[6,159,160]. In addition, lower vagus nerve activity, determined by heart rate variability
analysis is documented in autonomic dysfunction reported in obesity, the metabolic
syndrome and type 2 diabetes [6,161,162]. VNS, a clinically approved approach for treating
depression and epilepsy has been associated with weight loss, which is more substantial in
patients with higher degree of obesity [163]. Inflammation in obesity represents an
important therapeutic target in alleviating insulin resistance and other obesity-related
complications. Exploring vagus nerve-based cholinergic neurocircuitry in metabolic and
inflammatory regulation in obesity is an emerging approach that has been experimentally
tested by using cholinergic modalities, including the acetylcholinesterase inhibitor
galantamine [164] and α7nAChR agonists [165,166]. Galantamine treatment of mice with
high fat-induced obesity and the metabolic syndrome prevents further body weight gain and
significantly decreases glucose and insulin levels and insulin resistance [164]. In addition,
galantamine lowers leptin, resistin and IL-6 levels and attenuates fatty liver disease in these
mice [164]. A very recent study significantly substantiated these findings by demonstrating
the therapeutic anti-inflammatory and disease-alleviating efficacy of galantamine in an
animal model of type 2 diabetes [167]. These beneficial metabolic and anti-inflammatory
effects of galantamine, other cholinergic modalities and VNS in experimental settings of
obesity and type 2 diabetes provide a platform for further exploration of these approaches in
the treatment of obesity-related disorders [6].
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There is a growing interest in inflammation in the context of cancer and especially in solid
tumors/cancers. Chronic inflammation holds an increased risk of developing cancer. On the
other hand, oncogene alterations and tumor progression are associated with forming tumorassociated microenvironment in which immune cells such as tumor associated macrophages
and T cells, and cytokines and other inflammatory products are active modulators of tumorassociated angiogenesis, progression and metastases [168]. Therefore, cancer related
inflammation has been actively studied in the pursuit of identifying new molecular targets
that can be explored to improve diagnosis and treatment. Implications of neurocircuitry and
axon guidance molecules, such as netrin-1 in cancer have been indicated [169,170]. A role
for the vagus nerve in cancer has also been reported. Unilateral cervical vagotomy has been
shown to promote lung, liver, kidney and adrenal metastases in experimental 4THMpc
breast carcinoma, suggesting a tonic protective effect of the vagus nerve against metastatic
disease in this context [171,172]. In line with these observations, higher baseline high
frequency of heart rate variability, which is indicative for higher vagal tone is associated
with significantly longer survival of patients with metastatic and recurrent breast cancer
[173]. Bilateral subdiaphragmatic vagotomy promotes the development of experimental
carcinogen-induced pancreatic [174] and gastric cancer [175,176]. In contrast to these
observations, vagotomy has been found to suppress the development of gastric cancer
through a mechanism involving signaling through M3 mAChRs [177]. Subdiaphragmatic
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vagotomy has been clinically used in the treatment of ulcer. Vagotomy in these settings has
been associated with increased rate of cancer development and mortality of gastric,
colorectal, biliary tract, and lung cancer [178–181]. Lower vagal tone (based on heart rate
variability analysis) is associated with higher risk of 7-day mortality in patients with
advanced pancreatic and other non-lung cancers [182] and in patients with colorectal,
pancreatic, prostate, lung and ovarian cancer as compared to healthy individuals [183]. In
addition to a role in immune and metabolic control, reflex neuronal regulation, involving the
vagus nerve, of the inflammatory tumor microenvironment has been proposed [184–186].
Further studying this regulation and the role of the vagus nerve and other peripheral nerves
in the complex cancer-inflammation relationship hold significant promises for new
therapeutic approaches.

7. Translational implications
Author Manuscript

Ongoing in vitro and in vivo preclinical research has identified neuronal circuits with a role
in the regulation of immunity and inflammation, characterized cellular and molecular
mechanisms mediating these pathways and examined the therapeutic efficacy of their
modulation. Studies translating this insight into clinical settings were also initiated. These
studies may validate the therapeutic efficacy of new anti-inflammatory compounds, devicegenerated neuromodulation or combinations of these two strategies [187].
7.1. Pharmacological interventions
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A role for activation of the cholinergic anti-inflammatory pathway by utilizing α7nAChR
agonists or centrally-acting acetylcholinesterase inhibitors in ameliorating inflammation and
alleviating disease severity has been shown in various disease models, including septic
shock, severe sepsis, hemorrhagic shock, rheumatoid arthritis, inflammatory bowel disease,
obesity and type 2 diabetes [6,70,188]. These preclinical insights have paved the way to
clinical exploration of these modalities. The anti-inflammatory effects of the α7nAChR
agonist GTS-21 in doses, previously reported to be safe in humans [189] have been studied
in human endotoxemia [190]. GTS-21 anti-inflammatory effects have overall been found not
statistically significant as compared to the placebo-controlled group [190]. However, a
correlation between higher GTS-21 plasma levels and lower plasma levels of TNF, IL-6 and
IL-1 receptor agonist has been found [190]. It is an open question whether a higher dose of
GTS-21 will generate pronounced anti-inflammatory effects. The efficacy of the α7nAChR
agonist choline has been studied in patients with asthma. Choline treatment significantly
lowers TNF and other inflammatory markers, suppresses oxidative stress and alleviates
disease scores [191]. An important new area for clinical studies on the efficacy of α7nAChR
agonists and galantamine is the spectrum of obesity-driven disorders [6]. An ongoing
clinical study evaluates the effects of the selective α7nAChR agonist TC-6987 in type 2
diabetes https://clinicaltrials.gov/ct2/show/NCT01293669?term=Targacept&rank=11).
Performing clinical trials with galantamine and other centrally-acting acetylcholinesterase
inhibitors can be facilitated by the abundant clinical database available for these drugs and
their FDA approval for the symptomatic treatment of Alzheimer’s disease. The efficacy of
galantamine in doses, which are clinically approved for Alzheimer’s disease, is currently
being examined in individuals with the metabolic syndrome (https://clinicaltrials.gov/ct2/
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show/NCT02283242?term=cholinergic+obesity&rank=2). Using galantamine and other
centrally-acting acetylcholinesterase inhibitors with proven efficacy in improving memory
and cognition might address another important aspect in obesity-driven disorders. These
diseases and specifically type 2 diabetes are associated with certain degree of cognitive
dysfunction [140]. Accordingly, the need for prevention or alleviation of this cognitive
deterioration in strategizing new therapeutic approaches for the treatment of type 2 diabetes
has been emphasized [140].
7.2. Bioelectronic medicine
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The discovery of neuronal circuits in the regulation of immunity and inflammation at the
Feinstein Institute and other research centers has importantly contributed to the foundation
of Bioelectronic Medicine. This emerging field focuses on studying neuronal networks that
target molecular mechanisms of disease, and using neuromodulation by bioelectronic
devices as treatment. The need for new therapeutic approaches under the umbrella of
Bioelectronic Medicine is dictated by the lack of efficient pharmaceutical options in the
treatment of some diseases, significant side effects of currently used drugs, and the
astronomical cost of some pharmacological remedies. Biolelectronic medicine brings
together Molecular Medicine, Neuroscience, and Bioengineering. Basic and clinical
scientists with various background, skills, and different viewpoints are engaged in major
team efforts to address challenging questions in translating preclinical findings in
bioelectronic approaches to treat diseases. The use of electricity, i.e. VNS has been pivotal
in evaluating the therapeutic potential of neuromodulation in preclinical settings of various
inflammatory and autoimmune disorders, including rheumatoid arthritis. The therapeutic use
of electricity has a long history. It dates back to Scribonius Largus, the court physician of
the Roman emperor Claudius. It is intriguing that by using a natural “device”, a live torpedo
fish as a source of electricity, he was able to treat gout, a form of inflammatory arthritis. If
we fast-forward to the present, we get to the modern era of utilizing electricity in the
treatment of rheumatoid arthritis, but this time by electrical VNS through an implanted
device in a successful clinical trial [7]. This and other ongoing studies with implanted device
VNS in patients with inflammatory bowel disease (https://clinicaltrials.gov/ct2/show/
NCT02311660?term=vagus+nerve+stimulation&rank=8, https://clinicaltrials.gov/ct2/show/
NCT01569503?term=vagus+nerve+stimulation&rank=7) validate targeted neuromodulation
in disease treatment. Continuous research efforts focusing on the neuroanatomical and
functional evaluation of neural networks to target specific molecular mechanisms of disease
are likely to culminate in new clinical trials. Preclinical research has multiple aspects,
including neuroanatomical mapping of peripheral organ innervations, determining patterns
of peripheral autonomic and somatic nerve activity associated with certain disease
conditions, characterizing the specificity of interaction between nerves and muscle cells,
glandular cells, immune cells and other types of cells, and elucidating intracellular and
molecular mechanisms of these interactions. These research efforts go hand in hand with
developing new technology, including miniaturized devices and electrodes and optogenetic
methodology suitable for better interrogation of discrete neuronal circuits, imaging systems,
biocompatible materials, and programs for processing and analyzing large sets of data. The
therapeutic scope of bioelectronic neuromodulation is not limited to the treatment of
inflammatory and autoimmune diseases. Continuous progress in evaluating the role of
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neuronal circuitry in obesity-driven diseases, cancer and other debilitating and lifethreatening disorders and identifying related molecular targets holds a significant promise to
provide a rationale necessary for designing new therapeutic strategies based on
neurostimulation or neuroinhibition to treat these diseases.

8. Conclusions and future directions
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We have summarized here findings highlighting interactions between the nervous system
and the immune system. Vagus nerve-mediated and other neural circuits operating on reflex
principles regulate multiple aspects of immunity and inflammation. On the other hand,
dysregulated immune activation is associated with altered vagus and other peripheral nerve
activity and may cause brain neuronal dysfunction. Preclinical research has identified
several points of the reciprocal nervous system – immune system relationship and its
intersections with metabolism and behavior that can be explored in new therapeutic
strategies. Studying the role of cholinergic signaling in neuro-immune interactions in
various conditions characterized by adverse inflammation has validated the antiinflammatory and disease-alleviating properties of α7nAChR agonists, centrally-acting
acetylcholinesterase inhibitors and M1 mAChR agonists. Clinical testing of some of these
compounds has also been initiated. In parallel, evaluating the anti-inflammatory efficacy of
VNS and advanced understanding of neural circuitry controlling inflammation has allowed
implementation of conceptually novel platforms of disease treatment based on
neuromodulation within the scope of Bioelectronic Medicine. There is more to learn going
forward. Continuous research will further elucidate molecular and cellular mechanisms
underlying neuro-immune interactions and delineate discrete neuronal circuitry that can be
explored for therapeutic benefit. The current clinical testing of VNS in inflammatory and
autoimmune disorders promises to be the beginning of the use of bioelectronic technology in
safe, inexpensive and efficient treatments of a broad spectrum of diseases.
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Fig. 1. The functional anatomy of the inflammatory reflex
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Inflammatory mediators, such as cytokines, are released by activated macrophages and other
immune cells when TLRs and NLRs are activated upon immune challenge. These mediators
are detected by sensory components of the afferent arm of the inflammatory reflex (red).
Neuronal interconnections between the NTS, AP, DMN, NA, and higher forebrain regions
(not shown) integrate afferent signaling and efferent vagus nerve-mediated
immunoregulatory output. Efferent vagus nerve cholinergic output to the spleen, liver and
gastrointestinal tract (blue) regulates immune activation and suppresses pro-inflammatory
cytokine release (dotted red lines). Efferent vagus nerve fibers interact with the splenic
nerve to suppress pro-inflammatory cytokine release in spleen – a major organ source of
TNF and other pro-inflammatory cytokines in endotoxemia and other inflammatory
conditions. This efferent cholinergic arm of the inflammatory reflex is termed the
cholinergic anti-inflammatory pathway and can be activated in the brain through mAChR-
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mediated mechanisms triggered by M1 mAChR agonists and other mAChR ligands, and
AChE inhibitors, such as galantamine. Abbreviations: AChE, acetylcholinesterase; AP, area
postrema; DMN, dorsal motor nucleus of the vagus nerve; LPS, lipopolysaccharide
(endotoxin); mAChR, muscarinic acetylcholine receptor; NA, nucleus ambiguus; NLRs,
nucleotide-binding oligomerization domain-like receptors; NTS, nucleus tractus solitarius;
TLR4, toll-like receptor 4. (Adapted from [6])
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Fig. 2. Peripheral inflammation, autoimmunity and brain function: from sickness behavior to
neurological complications
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The impact of peripheral immune activation with the release of cytokines and other
inflammatory molecules on the brain is manifested by a spectrum of alterations, known as
sickness behavior. This is an important adaptive mechanism of brain function in acute
inflammatory conditions. Peripherally released pro-inflammatory cytokines signal the brain
through afferent vagus neurons, circumventricular organs, and other mechanisms [8,25,26]
(not shown). Peripheral inflammation with the release of cytokines also triggers brain proinflammatory signaling, which plays an important mediating role in sickness behavior. Brain
function alterations and neurological complications are described in numerous inflammatory
and autoimmune disorders. Dysregulations in neurotransmitter systems, cerebral blood flow
and microcirculation, brain metabolic activity, and brain pro-inflammatory signaling
underlie these neurological complications, which can be manifested by cognitive
deterioration, behavioral derangements and characteristic encephalopaties. These
neurological conditions can be debilitating and life-threatening and need to be properly
diagnosed and treated.
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